(Bloomberg) — Biogen is set to rack up its longest losing streak in over two years after the biotech company confirmed Wall Street fears that the rollout of its Alzheimer’s drug wasn’t going as well as hoped.
The stock fell for a seventh day on Thursday, solidifying roughly $7 billion loss after management said the introduction of Aduhelm was facing several challenges. The shares dropped 7.9 percent to $296.22 as of 12:32 p.m. in New York.
‘The launch is slower than we initially anticipated,’
https://www.bostonglobe.com/2021/09/09/business/biogen-loses-7-billion-value-slow-alzheimers-drug-rollout
